MedTrace Logo

Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

NCT06893016 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 640

Last updated 2025-07-17

No results posted yet for this study

Summary

The primary objective of this study is to demonstrate that RAY1225 is superior to placebo for percent change in body weight.

Conditions

Interventions

DRUG

RAY1225

RAY1225 will be administered SC

DRUG

Placebo

Placebo will be administered SC.

Sponsors & Collaborators

  • Guangdong Raynovent Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-15
Primary Completion
2026-06-15
Completion
2026-09-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06893016 on ClinicalTrials.gov